NCT05137756

Brief Summary

The aim is to evaluate the correlation of quantified fibro-adipous infiltration of muscles, using the MRI-based Mercuri score, with deficiencies, activity limitations and social participation in patients with arthrogryposis multiplex congenita.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2019

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 16, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 30, 2021

Completed
Last Updated

November 30, 2021

Status Verified

November 1, 2021

Enrollment Period

1.6 years

First QC Date

November 16, 2021

Last Update Submit

November 16, 2021

Conditions

Keywords

Arthrogryposis Multiplex CongenitaMRImercuri scorefibro-adipous infiltrationfonctionnal capacityrehabilitationretrospective observationnal study

Outcome Measures

Primary Outcomes (1)

  • Mercuri Scores of upper limbs, lower limbs,and trunk evaluated on MRI T1

    The degree of muscle fat infiltration was assessed with at least 2 visible slices. We used the four-point scale proposed by Mercuri et al 2002. Each muscle was staged as follows: 1. Normal appearance, 2. Mild involvement. 3. Moderate involvement. 4. Severe involvement.

    during 5 day evaluation

Secondary Outcomes (10)

  • muscle weakness

    during 5 day evaluation

  • passive range of motion

    during 5 day evaluation

  • 6 minutes walking test

    during 5 day evaluation

  • reaching score

    during 5 day evaluation

  • Functionnal independance measure

    during 5 day evaluation

  • +5 more secondary outcomes

Study Arms (2)

Amyoplasia

patient with diagnosis of Amyoplasia

Other: no intervention

Distal arthrogryposis

patient with diagnosis of Distal arthrogryposis

Other: no intervention

Interventions

no intervention

AmyoplasiaDistal arthrogryposis

Eligibility Criteria

Age17 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adults with a diagnostic of Amyoplasia or distal arthrogryposis, evaluated by a all body MRI, and functionnal evaluation during day hospitalisation in adult neurorehabilitation department of grenoble, between 2010 and october 2020

You may qualify if:

  • adults
  • with a diagnostic of Amyoplasia or distal arthrogryposis
  • evaluated by a all body MRI
  • functionnal evaluation during day hospitalisation in neurorehabilitation department
  • between 2010 and october 2020

You may not qualify if:

  • other aetiology of Arthrogryposis multiplex congenita (AMC)
  • incomplete MRI or medical files
  • interaction with other disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Grenoble Alpes

La Tronche, 38700, France

Location

Related Publications (5)

  • Liu CY, Yao J, Kovacs WC, Shrader JA, Joe G, Ouwerkerk R, Mankodi AK, Gahl WA, Summers RM, Carrillo N. Skeletal Muscle Magnetic Resonance Biomarkers in GNE Myopathy. Neurology. 2021 Feb 2;96(5):e798-e808. doi: 10.1212/WNL.0000000000011231. Epub 2020 Nov 20.

    PMID: 33219145BACKGROUND
  • Hall JG. Arthrogryposis multiplex congenita: etiology, genetics, classification, diagnostic approach, and general aspects. J Pediatr Orthop B. 1997 Jul;6(3):159-66.

  • Mercuri E, Pichiecchio A, Counsell S, Allsop J, Cini C, Jungbluth H, Uggetti C, Bydder G. A short protocol for muscle MRI in children with muscular dystrophies. Eur J Paediatr Neurol. 2002;6(6):305-7. doi: 10.1016/s1090-3798(02)90617-3.

  • Figueroa-Bonaparte S, Segovia S, Llauger J, Belmonte I, Pedrosa I, Alejaldre A, Mayos M, Suarez-Cuartin G, Gallardo E, Illa I, Diaz-Manera J; Spanish Pompe Study Group. Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function. PLoS One. 2016 Oct 6;11(10):e0163493. doi: 10.1371/journal.pone.0163493. eCollection 2016.

  • Dai S, Dieterich K, Jaeger M, Wuyam B, Jouk PS, Perennou D. Disability in adults with arthrogryposis is severe, partly invisible, and varies by genotype. Neurology. 2018 May 1;90(18):e1596-e1604. doi: 10.1212/WNL.0000000000005418. Epub 2018 Apr 6.

MeSH Terms

Conditions

Arthrogryposis

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesMuscular DiseasesMusculoskeletal AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Dominic PERENNOU, MDPHD

    CHU Grenoble Alpes

    STUDY DIRECTOR
  • Klaus DIETERICH, MD

    CHU Grenoble Alpes

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 16, 2021

First Posted

November 30, 2021

Study Start

December 1, 2019

Primary Completion

July 1, 2021

Study Completion

October 1, 2021

Last Updated

November 30, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will not share

Locations